# The Hope Foundation: Supporting SWOG Cancer Research Network

Generated by Yoast SEO v28.4, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Documents](https://thehopefoundation.org/about/documents/)
- [Thank You](https://thehopefoundation.org/donate/thank-you/)
- [Ways to Give](https://thehopefoundation.org/donate/ways-to-give/)
- [Donate](https://thehopefoundation.org/donate/)
- [Cancer Care \& Support](https://thehopefoundation.org/cancer-care-support/)

## Posts
- [Annual Call for Funding Requests Open for 2027](https://thehopefoundation.org/news/annual-call-for-funding-requests-open-for-2027/)
- [Honoring Veterans with Access to the Best Cancer Care](https://thehopefoundation.org/news/honoring-veterans-access-best-cancer-care/)
- [Running to Advance Cancer Research](https://thehopefoundation.org/news/running-to-advance-cancer-research/)
- [2026 Foundation Budget Announced](https://thehopefoundation.org/news/2026-foundation-budget-announced/)
- [SWOG Establishes An APP \& Nurse Scientist Committee](https://thehopefoundation.org/news/swog-establishes-an-app-nurse-scientist-committee/)

## Breakthroughs
- [30 Years of Supporting SWOG and Advancing Cancer Care](https://thehopefoundation.org/breakthroughs/30-years-of-supporting-swog-and-advancing-cancer-care/): In 2023, The Hope Foundation honored its 30 years of support for SWOG with a series of audio stories and a comprehensive written history\.
- [Carboplatin Becomes Standard for Ovarian Cancer](https://thehopefoundation.org/breakthroughs/carboplatin-becomes-standard-for-ovarian-cancer/): SWOG S8412 demonstrated carboplatin was as effective and less toxic than cisplatin, leading to its FDA approval as the standard treatment for ovarian cancer\.
- [15\-Year Results from SWOG’s S0016 Study Suggest Follicular Lymphoma Is Curable](https://thehopefoundation.org/breakthroughs/15-year-results-from-swogs-s0016-study-suggest-follicular-lymphoma-is-curable/): A new long\-term study challenges the belief that advanced follicular lymphoma is incurable, finding that about 42% of patients treated with standard therapy may be effectively cured and remain cancer\-free for life\.
- [A Clear Winner Emerges for a Rare, Hard\-to\-Treat Kidney Cancer](https://thehopefoundation.org/breakthroughs/a-clear-winner-emerges-for-a-rare-hard-to-treat-kidney-cancer/): A major clinical trial found that cabozantinib significantly improves outcomes for patients with metastatic papillary kidney cancer, leading to a new standard of care\.
- [New Immunotherapy Combination Standard for Hodgkin Lymphoma](https://thehopefoundation.org/breakthroughs/new-standard-for-advanced-hodgkin-lymphoma/): The SWOG S1826 trial established nivolumab plus AVD chemotherapy as the new standard of care for advanced Hodgkin lymphoma, replacing brentuximab vedotin \+ AVD with a regimen showing superior progression\-free survival and fewer toxic side effects\.

## Programs
- [VA Staff Travel Support Program](https://thehopefoundation.org/programs/va-staff-travel-support-program/)
- [CRA/Nurse Travel Support Program](https://thehopefoundation.org/programs/cra-nurse-travel-support-program/)
- [VA Storefront Support Program](https://thehopefoundation.org/programs/va-storefront-support-program/)
- [Leadership and Project Development Course](https://thehopefoundation.org/programs/leadership-project-development-course/)
- [Committee Meeting Funds](https://thehopefoundation.org/programs/committee-group-meeting-funds/)

## Focus Areas
- [Lung Cancer](https://thehopefoundation.org/focus-areas/lung-cancer/): 20 active studies open to enrollment or gathering long\-term follow up data\.
- [Leukemia](https://thehopefoundation.org/focus-areas/leukemia/): 8 active studies open to enrollment or gathering long\-term follow up data\.
- [Myeloma](https://thehopefoundation.org/focus-areas/myeloma/): 7 active studies open to enrollment or gathering long\-term follow up data\.
- [Lymphoma](https://thehopefoundation.org/focus-areas/lymphoma/): 7 active studies open to enrollment or gathering long\-term follow up data\.
- [Melanoma](https://thehopefoundation.org/focus-areas/melanoma/): 6 active studies open to enrollment or gathering long\-term follow up data\.

## Categories
- [Foundation News](https://thehopefoundation.org/news/category/foundation-news/)
- [Feature](https://thehopefoundation.org/news/category/feature/)
- [Group Meetings](https://thehopefoundation.org/news/category/group-meetings/)
- [Kilimanjaro Chronicle](https://thehopefoundation.org/news/category/kilimanjaro-chronicle/)
- [General](https://thehopefoundation.org/news/category/general/)

## Tags
- [Group Meetings](https://thehopefoundation.org/news/tag/group-meetings/)
- [\#SWOGonc](https://thehopefoundation.org/news/tag/swogonc/)
- [Coltman Fellow](https://thehopefoundation.org/news/tag/coltman-fellow/)
- [VA](https://thehopefoundation.org/news/tag/va/)
- [Impact Award](https://thehopefoundation.org/news/tag/impact-award/)

## Optional
- [Sitemap index](https://thehopefoundation.org/sitemap_index.xml)